EVIDENCE LIBRARY
Poststroke Sleep Review Based Clonazepam Parasomnia Discussion on Limited Case Evidence
A literature review distinguished stronger sleep-breathing evidence from much thinner evidence for treating poststroke sleep–wake symptoms. Its clonazepam discussion was not a clinical trial finding.
A literature review distinguished stronger sleep-breathing evidence from much thinner evidence for treating poststroke sleep–wake symptoms. Its clonazepam discussion was not a clinical trial finding.
Different disorders and evidence levels
The review addressed sleep-disordered breathing, insomnia, hypersomnia, restless legs, and parasomnias in people with stroke. It discussed the high prevalence of breathing disorders and evidence concerning their treatment.
For several sleep–wake treatments, including clonazepam for parasomnias, the authors stated that support was based on single case observations and urged caution.
One section cannot borrow another’s certainty
Evidence supporting treatment of obstructive sleep-disordered breathing does not establish clonazepam efficacy for poststroke parasomnia. These interventions address different mechanisms and outcomes.
The review also drew on experimental work concerning recovery and neuroplasticity. Such mechanisms are distinct from demonstrated functional recovery in treated human patients. A review’s general conclusion should not erase those differences.
Practical interpretation
Identify the actual sleep diagnosis, breathing findings, stroke-related deficits, and treatment objective. A prescription intended to suppress a parasomnia is not evidence that breathing problems were treated or that rehabilitation improved. This review can organize relevant questions, but cannot provide a reliable clonazepam response rate or prove benefit for every poststroke sleep complaint.
Source paper
Original analysis of the supplied journal article, identified as PMC5047039.